News

Venaxis Reports on Recent FDA Submission Activities

Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1™ Test, a rapid, multi-analyte assay for aiding in identifying children, adolescent and young adult patients that are at low risk for appendicitis, updated on recent activities concerning its U. S. Food and Drug Administration (FDA) submission for the APPY1 Test that was filed in March 2014.  Read more…



Venaxis to Present at ICV Company Outreach Summit

Venaxis, Inc. today announced it will participate in the third annual ICV Company Outreach Summit, being held July 9-10, 2014, in Montauk, New York. Steve Lundy, President and CEO of Venaxis® will be presenting at the conference to investors including representatives from hedge and private equity funds as well as high net worth individuals and family funds.  Read more…



Venaxis to Participate in 11th Annual Craig-Hallum Institutional Investor Conference

Venaxis, Inc. announced it will participate in the 11th Annual Craig-Hallum Institutional Investor Conference, to be held May 28, 2014, at the Minneapolis Marriott City Center.  Read more…